Molecular Targeting for Epidermal Growth Factor Receptor Expressed on Breast Cancer Cells by Human Fusion Protein

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Recombinant human ribonuclease 1 (RNase 1) is an enzyme with potential therapeutic applications.
• Epidermal growth factor (EGF) plays a crucial role in cell growth and is often overexpressed in various cancers.
• Targeted drug delivery systems aim to enhance therapeutic efficacy while minimizing side effects.

Purpose of the Study:

• To synthesize and characterize a novel conjugate of human RNase 1 and human EGF.
• To evaluate the in vitro cytotoxicity of the EGF-RNase conjugate against cancer cell lines.
• To determine the correlation between conjugate efficacy and epidermal growth factor receptor (EGFR) expression.

Main Methods:

• Chemical linkage of recombinant human RNase 1 to recombinant human EGF.
• Cytotoxicity assessment using the MTT assay.
• Analysis of conjugate efficacy in relation to EGFR expression levels in breast and squamous cell carcinoma lines.

Main Results:

• The EGF-RNase conjugate exhibited dose-dependent cytotoxicity against cancer cells.
• Cytotoxicity was significantly higher in cell lines with elevated EGFR expression.
• A positive correlation was observed between EGFR expression levels and conjugate efficacy.

Conclusions:

• The EGF-RNase conjugate represents a promising targeted anticancer agent.
• This conjugate demonstrates enhanced efficacy and potentially reduced toxicity compared to conventional treatments.
• Targeting EGFR-overexpressing cancers with the EGF-RNase conjugate is a viable therapeutic strategy.